Trials / Completed
CompletedNCT01622543
Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer
A Randomized Phase II Study of Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Patients With Metastatic Colorectal Cancer.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 109 (actual)
- Sponsor
- Canadian Cancer Trials Group · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out if giving reolysin in combination with FOLFOX6/ bevacizumab can offer better results than standard therapy with FOLFOX6/ bevacizumab.
Detailed description
Researchers doing this study also want to evaluate the side effects of reolysin when given together with FOLFOX6/ bevacizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Folfox plus Bevacizumab and reolysin | FOLFOX6/bevacizumab given every 14 days plus reolysin days 1-5 on cycles 1, 2, 4, 6, 8 and alternate cycles thereafter |
| DRUG | Folfox plus Bevacizumab | FOLFOX6/bevacizumab given every 14 days. |
Timeline
- Start date
- 2012-10-26
- Primary completion
- 2017-01-18
- Completion
- 2018-09-12
- First posted
- 2012-06-19
- Last updated
- 2023-08-23
- Results posted
- 2019-12-13
Locations
10 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT01622543. Inclusion in this directory is not an endorsement.